Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary phosphocreatine for myocardial microvascular dysfunction
ChiCTR1900021807Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Mar 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of phosphocreatine and nicorandil in coronary arteriosclerosis and Coronary Small Vessel Disease (CMD) (3 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Microvascular resistance index. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
phosphocreatinenicorandil
03
Conditions
coronary arteriosclerosisCoronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR1900021807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021807.